Investors

Viral Therapeutics, Incorporated is a privately held, rapidly growing company with proprietary technologies. With an experienced management team and scientific staff, we are well-positioned to move our proprietary technologies and product development to the marketplace.

The VTI Advantage:

• Intellectual Property Portfolio

  • Vagiprev exclusive worldwide rights
  • Virus or exclusive worldwide rights
  • Protein manufacturing technology (70 patents, Research Corporation Technologies)
  • Herpes HSV recombinant protein license (25 patents, Chiron Corporation)
  • Pharmacogenetics Portfolio:
  • 11 Final Filings encompassing 34 diseases, 7 genes, and 336 SNP disease associations
  • 96 Patent claims for end-stage renal disease treatment
  • 10,000 Human Leukocyte samples comprising over 120 diseases

If you are interested in further investment information, please contact:

Viral Therapeutics, Incorporated
Attn:  Lee Henderson, Ph.D.
Cornell Business and Technology Park
33 Thornwood Drive, Suite 104
Ithaca, NY 14850

[email protected]

607-266-0860
607-257-6356 (fax)